For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenues | - | 6,608 | 3,681 | 2,765 |
| Cost of royalties | - | 80* | 5 | 39 |
| Research and development | - | 8,238 | 3,271 | 3,106 |
| General and administrative | - | 4,852 | 4,191 | 4,560 |
| Gain on impairment of intangible asset (note 6 and note 13) | - | -14* | 0 | 14,840 |
| Total operating expenses | - | 13,156 | 7,467 | 22,545 |
| Loss from operations | - | -6,548 | -3,786 | -19,780 |
| Interest income, net | - | 393 | 366 | 454 |
| Loss on marketable equity securities, net | - | -7 | 6 | -2 |
| Change in fair value of warrant liability | - | -1,265 | 26,557 | 12,740 |
| Foreign currency transaction gain (loss), net | - | 482 | 219 | 1,678 |
| Other income (expense), net | - | 27 | 0 | 26 |
| Total other income (expenses) | - | 2,160 | -25,966 | -10,584 |
| Loss before income taxes | - | -428* | - | - |
| Income tax benefit | - | -1,320* | - | - |
| Net gain | -4,789 | 892 | -29,752 | -30,364 |
| Net (income) loss attributable to noncontrolling interest | 23 | 41 | 29 | 100 |
| Net gain attributable to lineage | -4,812 | 851 | -29,781 | -30,464 |
| Basic EPS | -0.02 | 0.004 | -0.13 | -0.13 |
| Diluted EPS | -0.03 | 0.004 | -0.13 | -0.13 |
| Basic Average Shares | 245,029,000 | 237,201,000 | 228,853,000 | 228,356,000 |
| Diluted Average Shares | 261,175,000 | 237,201,000 | 228,853,000 | 228,356,000 |
Lineage Cell Therapeutics, Inc. (LCTX)
Lineage Cell Therapeutics, Inc. (LCTX)